Metabolic reprogramming is implicated in drug resistance,[59–61] and studies have revealed that IMPDH2-mediated purine metabolism promotes oxaliplatin resistance in colorectal cancer by suppressing caspase-dependent apoptosis.[7] In diffuse midline gliomas, inhibition of purine salvage may contribute to overcoming treatment resistance.[62] Notably, our findings demonstrate significant associations between PMRGs and drug sensitivity, thereby providing further potential targets for investigating cancer drug resistance. Here, IMPDH2 is linked to colorectal cancer.